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Worldwide, use of long-acting reversible contraception (LARC) has easily overtaken oral 
contraceptive use, now with double the prevalence.1 Rates of LARC (defined as subdermal 
implants, intrauterine contraceptives and injectables) use are twice as high in the 
developing world as in the developed world.1 There are many reasons for this increasing use 
of LARC, some to do with potential users and some to do with advocates of LARC. There has 
been a general increase in public awareness and knowledge of and confidence in LARC. 
Amongst advocates, to mention only a few reasons, there has been a shift in medical 
opinion about the safety of postplacental insertion of intrauterine contraception (IUC) 
facilitating more postpartum uptake2, considerable focus on postabortion contraception3 
and offering IUC to nulliparas has become more mainstream4. Price-lowering initiatives have 
also contributed enormously to the expansion of availability of LARC.5 
 
Other forces work in the opposite direction, not all of them understood. For example, in 
Australia, despite higher levels of awareness of LARC than in many other countries, a 
majority of women and men do not consider that these methods are reliable and so would 
not use them.6 Across five countries in Europe, one third of women will not contemplate 
using IUC as it may have post-fertilisation effects.7 US expert opinion is that, even with all 
barriers to access removed, ultimately fewer than one-third of women will choose LARC.8 
 
Facilitating access to LARC is widely regarded as an important public health measure with 
which to reduce unintended pregnancy. It has been shown in the USA that a LARC training 
intervention for providers can lower pregnancy rates amongst those attending for 
contraceptive services.9 It is, however, important to guard against the notion that LARC is 
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itself the main solution to the issue of unintended pregnancy. When reading reports of 
programmes such as the CHOICE Project,10 it is tempting to conclude that the more women 
who move to using LARC the better. However, it has been calculated that most of the 
'CHOICE effect' could have been achieved not by an increase in LARC use, but by adoption of 
pills, patches and vaginal rings by non-users and condom users.11  
 
When undertaking the care of contraceptive users, comprehensive information about the 
full range of methods should be provided. An individual woman being counselled about her 
contraceptive choices must be free to make her own decision, which will not necessarily 
align with what is epidemiologically the best option for curbing fertility rates. Particular 
demographic groups targeted by LARC promotion programmes include young women12 and 
those undergoing abortion.13 Some British healthcare professionals feel that their clinical 
management is being overly influenced by LARC targets imposed on them by policy makers 
and service managers, eroding their freedom to respond to women’s needs.14 US 
contraceptive expert attitudes are strongly against incentivisation of women to use LARC 
and almost as strongly against incentivisation of clinicians to initiate LARC. 8 Clinicians need 
to take care - when they have ‘dual agent’15 roles, acting both on behalf of individual 
patients and the demands of public health - that their professional obligations to a patient 
come first. The carefully crafted World Health Organization tiered-effectiveness model of 
contraceptive counselling mentions LARC methods first but respects women’s autonomy in 
decision-making.16 
 
Provider bias for or against LARC has been reported.16 This takes various forms and may be 
explicit or implicit. Negative professional attitudes to use of IUC by the young or nulliparous 
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are still widespread; insisting upon restrictive protocols - for example, two-visit insertion 
protocols - can inhibit access to LARC. 17 Clinicians need to improve their own knowledge 
and attitudes in order that they can assist women with 'myth-busting'. Preferential supply of 
LARC to particular racial groups or those of low socio-economic status18 is an unsavoury 
phenomenon, the precise extent of which is unknown. 
 
Some of the evidence for provider bias against LARC comes indirectly from women. There 
may be medical resistance to LARC with providers viewing women as ‘too young’.19 Some 
women report that they have had to be persistent and push to obtain LARC or, in some 
cases, try another hormonal method first as a precondition to receiving LARC. Young women 
report instances of provider resistance to requests for LARC removal when they are 
overwhelmed by side effects18.  
 
Although effectiveness is the prime characteristic most women seek when choosing a 
contraceptive method,16 there are many personal factors that inhibit women from adopting 
LARC methods. These include concerns, fears, perceptions and misperceptions. There are 
concerns about the possibility of known adverse effects such as irregular bleeding and 
‘visible’ side effects such as weight gain and groundless - but nevertheless strongly felt - 
fears of adverse outcomes such as interference with future fertility.20 Some young women 
feel disconcerted about the amount of hormone being released in their body21 despite the 
fact that the actual hormone levels are modest (implant) or low (intrauterine system); there 
is also a concern that hormone-release from the device could suddenly cease. Some 
(especially young) women are wary of the implant due to its visibility and the possibility of 
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alerting others to their sexual activity21; in this respect the derogatory term ‘slag-tag’ is now 
widespread in the British vernacular and has been used to stigmatise younger women.  
 
Amongst young American women there is uneasiness about LARC and negative descriptions 
of the methods either in mechanistic terms (invasive, requiring surgery or ‘almost surgery’) 
or emotional terms (scary or, according to one woman, ‘oh, it’s an alien’).19 Some Australian 
women describe the implant as weird, bizarre, creepy or even akin to being microchipped.22 
There are also misconceptions about risks and feelings that LARC methods would only be 
appropriate in a later phase of their lives.19, 20 Some fear needles or pain.20 IUC is ruled out 
for some women who cannot contemplate the prospect of undergoing an intimate 
examination at all or who have anxieties related to the embarrassment of insertion into 
‘private parts’ particularly if they were menstruating. Others have fantasies about an IUC ‘up 
in me’ ripping their internal organs, getting lost inside or becoming dislodged during sex.19, 20 
 
Power issues15 underlie the use of LARC, both in relation to interactions that occur within 
consultations with providers and in a woman’s ability to have control over her own 
contraceptive method. The delivery of contraception, which does not involve treating an 
illness, should be patient-centred; power imbalance should be minimal. Although the days 
of medical paternalism are generally thought to be over, care is needed to ensure that 
medical power is not over-used and that there is full respect for women’s autonomy and 
rights. In some countries there is a legacy of non-consensual sterilisation23 that continues to 
affect the confidence of the public in healthcare providers. Providing a reliable means to 
control her fertility empowers a woman, freeing her to pursue her interests and aspirations 
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and ultimately giving her the possibility of self-determination. In this regard, LARC methods 
are remarkable agents as they provide high effectiveness without the permanency of 
sterilisation. Many women value the ‘fit and forget’ property which gives them peace of 
mind.20 The contribution that LARC has made to allowing women to play a full part in society 
cannot be overstated.  
 
Despite all these positive attributes, LARC methods are essentially invasive. IUC and 
implants need to be inserted into the body and cannot generally be removed without 
medical assistance. This provider-dependence takes away control of starting and stopping 
these methods, a property valued by a substantial proportion of women,20 and so is 
relatively disempowering. However, cessation of injectables is under a woman's control. 
Subcutaneous depôt medroxyprogesterone acetate injections allow women themselves to 
continue and discontinue their LARC method.24 
 
There is a mismatch in perceptions between advocates of LARC and potential users. A public 
health approach supports less personal control over contraception so there is reduced room 
for error and therefore greater effectiveness and continuation. In contrast, women 
themselves often prefer to retain control over their contraceptive method.19, 20, 22 Many 
women are more comfortable using oral contraception because it is under their control,19 
despite its lower effectiveness.  Whilst there is general agreement that women should be 
offered the full range of methods, advocates may be biased towards preferentially 
promoting methods on the grounds of high effectiveness; there is a tension here as this can 
undermine women’s autonomy. Clinicians working in all settings need to appreciate more 
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how individuals make decisions about their method of contraception. Undue pressure to 
use a method is likely to result in higher dissatisfaction and discontinuation rates. 
 
In the USA, continuation rates with IUC and implants are higher than for combined 
hormonal methods; however, continuation rates for injectables are lower than for 
combined hormonal methods.25 Whether women continue or discontinue their LARC 
method depends on many factors. Once women become established on IUC or implants, 
satisfaction rates are remarkably high. Women who are more determined not to become 
pregnant are less likely to discontinue their LARC method, whereas those who experience 
side effects are more likely to discontinue. However, removals do not inevitably follow from 
side effects; the actual rate of side effects will always be many times higher than that of 
removals. Individuals follow a ‘balance sheet’ approach and weigh up the various factors for 
and against a particular method. Clinicians see women who persist with implants as their 
method despite many years of prolonged bleeding episodes; these tend to be older women 
whose families are complete. On the other hand, young women are generally less tolerant 
of problematic bleeding.14 
 
In summary, a patient-centred approach to contraceptive care is fundamental to women's 
autonomy. It needs to be appreciated that unintended pregnancy is most likely to be 
reduced by fulfilling unmet need for contraception and encouraging those not using any 
form of contraception, or condoms only, to use a method of their choice accompanied by 
adequate instruction (where necessary) in correct usage. Against this backdrop, however, 
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incentivisation of LARC use and target-driven LARC programmes could be seen to be 
problematic, as is patient targeting by demographics. Promotion of LARC over and above 
other contraceptive methods can lead to coercive practices. 
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